Michael  Rosenblatt net worth and biography

Michael Rosenblatt Biography and Net Worth

Director of Brooks Automation
Dr. Rosenblatt has been a director since September 2018. Dr. Rosenblatt currently serves as Chief Medical Officer of Flagship Pioneering, a Cambridge, Massachusetts-based firm that originates new biotech companies. Prior to Flagship Pioneering, from 2009 through 2016, he was Executive Vice President and Chief Medical Officer of Merck & Co., Inc., and prior to that he held various academic positions, including as Dean of Tufts University School of Medicine and the Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. Since 2015 Dr. Rosenblatt has been on the board of Rubius Therapeutics, a publicly traded company using advanced cellular approaches that harness properties of red blood cells to generate novel therapies. He has been a director of the following privately owned companies since 2016: Flagship Pioneering’s Cobalt Biomedicine, Cygnal Therapeutics, and Ohana Biosciences, and Ferring’s USA subsidiary. Dr. Rosenblatt is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of Massachusetts General, Brigham and Women’s, and Boston Children’s hospitals.

What is Michael Rosenblatt's net worth?

The estimated net worth of Michael Rosenblatt is at least $0.00 as of May 13th, 2021. Dr. Rosenblatt owns 7,882 shares of Brooks Automation stock worth more than $0 as of November 18th. This net worth estimate does not reflect any other assets that Dr. Rosenblatt may own. Learn More about Michael Rosenblatt's net worth.

How do I contact Michael Rosenblatt?

The corporate mailing address for Dr. Rosenblatt and other Brooks Automation executives is 15 Elizabeth Drive, Chelmsford MA, 01824. Brooks Automation can also be reached via phone at (978) 262-2400 and via email at [email protected]. Learn More on Michael Rosenblatt's contact information.

Has Michael Rosenblatt been buying or selling shares of Brooks Automation?

Michael Rosenblatt has not been actively trading shares of Brooks Automation within the last three months. Most recently, Michael Rosenblatt sold 2,831 shares of the business's stock in a transaction on Friday, November 12th. The shares were sold at an average price of $114.13, for a transaction totalling $323,102.03. Learn More on Michael Rosenblatt's trading history.

Who are Brooks Automation's active insiders?

Brooks Automation's insider roster includes David Gray (Insider), David Jarzynka (Insider), Jason Joseph (SVP), Joseph Martin (Director), William Montone (SVP), David Pietrantoni (Insider), Lindon Robertson (CFO), Michael Rosenblatt (Director), Stephen Schwartz (CEO), and Robin Vacha (SVP). Learn More on Brooks Automation's active insiders.

Michael Rosenblatt Insider Trading History at Brooks Automation

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/12/2021Sell2,831$114.13$323,102.03View SEC Filing Icon  
5/13/2021Sell1,760$90.00$158,400.007,882View SEC Filing Icon  
See Full Table

Michael Rosenblatt Buying and Selling Activity at Brooks Automation

This chart shows Michael Rosenblatt's buying and selling at Brooks Automation by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Brooks Automation Company Overview

Brooks Automation logo
Brooks Automation, Inc. is an automation provider and partner to the global semiconductor manufacturing industry. The firm focuses on providing advanced robots, vacuum automation systems, contamination control systems, and reticle storage solutions to OEMs and global semiconductor chip manufacturers. Its solutions include automations, PuroMaxx Contamination Control, and GuardianPro Clean Storage. The company was founded in 1978 and is headquartered in Chelmsford, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $112.50
Low: $98.67
High: $124.15

2 Week Range

Now: N/A

Volume

1,022,700 shs

Average Volume

777,497 shs

Market Capitalization

$8.41 billion

P/E Ratio

75.91

Dividend Yield

0.35%

Beta

1.77